Is there a role for melatonin in the treatment of neoplastic cachexia?

European Journal of Cancer Part A

Volumn 32, Issue 8, 1996, Pages 1340-1343

  Lissoni, P ^a   Paolorossi, F ^a   Tancini, G ^a   Barni, S ^a   Ardizzoia, A ^a   Brivio, F ^a   Zubelewicz, B ^b   Chatikhine, V ^c  

^a SAN GERARDO HOSPITAL   (Italy)

^b Division of Internal Medicine   (Poland)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

Melatonin; Neoplastic cachexia; Tumour necrosis factor alpha

Indexed keywords

MELATONIN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CACHEXIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOOD INTAKE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID TUMOR; WEIGHT REDUCTION;

EID: 0030056686     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00136-0     Document Type: Article

References (19)

1. Theologides A. The anorexia-cachexia syndrome. A new hypothesis. Ann NY Acad Sci 1974, 230, 427-434.
2. Waterhouse C. How tumors affect host metabolism. Ann NY Acad Sci 1974, 230, 89-93.
3. Tancini G, Barni S, Crispino S, Paolorossi F, Lissoni P. A study of thyroid function in cancer cachexia. Tumori 1989, 75, 185-188.
4. Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol 1994, 12, 213-225.
5. Beutler B, Cerami A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 1986, 320, 584-588.
6. Balkwill F, Osborne R, Burke F, et al. Evidence for tumor necrosis factor/cachectin production in cancer. Lancet 1987, II, 1229-1232.
7. Ardizzoia A, Lissoni P, Brivio F, et al. Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 1992, 6, 103-107.
8. Lissoni P, Barni S, Rovelli F, Tancini G. Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary report. Oncology 1991, 48, 125-127.
9. Jankovic BD. Neuroimmunomodulation. From phenomenology to molecular evidence. Ann NY Acad Sci 1994, 741, 1-38.
10. Regelson W, Pierpaoli W. Melatonin: a rediscovered antitumor hormone? Cancer Invest 1987, 5, 379-385.
11. Lissoni P, Tisi E, Brivio F, et al. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin. J Biol Regul Homeast Agents 1991, 5, 154-156.
12. Maestroni GJM, Conti A, Pierpaoli W. Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Ann NY Acad Sci 1988, 521, 140-145.
13. Lissoni P, Barni S, Tancini G, et al. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin. J Biol Regul Homeost Agents 1994, 8, 126-129.
14. Lissoni P, Viviani S, Bajetta E, et al. A clinical study of the pineal gland activity in oncologic patients. Cancer 1986, 57, 837-842.
15. Lissoni P, Barni S, Crispino S, Tancini G, Fraschini F. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol 1989, 25, 789-795.
16. Allegra JC, Kiefer SM. Mechanism of action of progestational agents. Semin Oncol 1985, 12 (Suppl. 1), 3-9.
17. Tracey KL, Lowry SF, Fahey TJ, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986, 234, 470-474.
18. Epstein FH. The L-arginine-nitric oxide pathway. N Engl J Med 1993, 329, 2002-2012.
19. Spessert R, Hill G, Layes E, Vollrath L. Adrenoceptor stimulation induces nitric oxide formation in rat pinealocytes. Acta Neurobiol Exp 1994, 54 (Suppl.), 97-98.